I summarise my understanding for a bit.

 

So apparently Aytu was importing Zhejiang / Healgen' s products beforehand. They declared that NMPA, China' s version of the FDA, had not approved it yet (also, " A U.S. expert said the Chinese agency is considered " rigorous" and " demanding" in its oversight of products" so quite credible la ah). At that time, US-side/FDA was ok. But on 1 April, China' s NMPA  banned exports if they never approve.

 

At that point, Aytu was supplying some organisations in Colorado already. So now Aytu has orders to fill, but no supplier. Problem. Opportunity for Bio.

 

Very interestingly, on April 10, Aytu released a press release that said that they had " placed an order for 1 million test kits from an unidentified manufacturer" and also have an " order for 500,000 tests was " awaiting customs clearance" " . Remember, they announced exclusive distributorship agreement yesterday on 23/04 only. Any guesses who the unidentified manufacturer is?

 

My guess is Biolidics lor. If that' s true, not only confirmed sales, but sales arrived in US already liao. Never announce at point of sale because maybe that time not exclusive distributor yet, so maybe not material (or maybe that' s why halt ahah)

 

So NMPA approval means high chance of FDA approval. Also, initial sales look like its locked in already. It looks promising to me le. Not sure yet about the price fluctuations. While I' m sure Abbott and Roche will remain markets leaders in the US (once they actually manage to ramp up manufacturing in a few months), it looks like Biolidics+Aytu will do quite well for themselves also. A main reason is that they are moving lightning fast.

 

I don' t know how to analyse stocks like you experts, so I just do this kind of research and use my experience. Does it make sense?